<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;table id="schedule" class="data" border="0" cellspacing="0" summary="This table shows the date, time, and location of the meeting" cellpadding="2" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;th id="a2" bgcolor="#cccccc" valign="top" width="35%" align="left" style="height: 19px"&gt;Date&lt;/th&gt;&lt;th id="a3" bgcolor="#cccccc" valign="top" width="30%" align="left" style="height: 19px"&gt;Time&lt;/th&gt;&lt;th id="a4" bgcolor="#cccccc" valign="top" width="45%" align="left" style="height: 19px"&gt;Location&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="35%" headers="a2" style="height: 64px"&gt;&lt;!-- InstanceBeginEditable name="col2" --&gt;February 25, 2010&lt;br /&gt;February 26, 2010 &lt;!-- InstanceEndEditable --&gt;&lt;/td&gt;&lt;td valign="top" width="30%" headers="a3" style="height: 64px"&gt;&lt;!-- InstanceBeginEditable name="col3" --&gt;8:00 a.m. - 5:00 p.m.&lt;br /&gt;8: 00 am - 2:00 p.m.&lt;!-- InstanceEndEditable --&gt;&lt;/td&gt;&lt;td valign="top" width="45%" headers="a4" style="height: 65px"&gt;&lt;p&gt;&lt;!-- InstanceBeginEditable name="col4" --&gt;The Hilton Hotel&lt;/p&gt;&lt;p&gt;8727 Colesville Road&lt;/p&gt;&lt;p&gt;Silver Spring, M.D. 20910&lt;!-- InstanceEndEditable --&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;h2 class="BlueBar"&gt;&lt;strong&gt;Agenda&lt;/strong&gt;&lt;/h2&gt;&lt;p&gt;&lt;!-- InstanceBeginEditable name="agenda" --&gt;On February 25 and 26, 2010, the committee will discuss strategies and lessons from a selection of FDA's previously issued communications, emphasizing communications challenges. Examples, selected for illustrative purposes only, will be drawn from communications about issues in broad areas such as biologics, drugs, medical devices, regulatory actions, and veterinary products. FDA intends to make agenda information available no later than 15 days before the meeting.&lt;/p&gt;&lt;h2 class="BlueBar"&gt;&lt;a href="[!--$ssLink(&amp;quot;ucm197164.htm&amp;quot;)--]"&gt;Other Meeting Materials&lt;/a&gt;&lt;/h2&gt;&lt;h2 class="BlueBar"&gt;Public Participation Information&lt;/h2&gt;&lt;p&gt;&lt;!-- InstanceBeginEditable name="pubpart" --&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&amp;nbsp;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Written submissions may be made to the contact person on or before February 17, 2010.&amp;nbsp;&lt;/li&gt;&lt;li&gt;Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. on February 25, 2010 and 10:30 a.m. and 11:30 a.m. on February 26, 2010. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentations on or before February 17, 2010.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by February 18, 2010.&lt;/p&gt;&lt;p&gt;&lt;!-- InstanceEndEditable --&gt;&lt;/p&gt;&lt;h2 class="BlueBar"&gt;&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/h2&gt;&lt;p&gt;&lt;!-- InstanceBeginEditable name="contact" --&gt;&lt;/p&gt;&lt;ul class="listspace"&gt;&lt;li&gt;&lt;strong&gt;Lee L. Zwanziger, Designated Federal Official&lt;/strong&gt;&lt;br /&gt;5600 Fishers Lane, Rm 14-90, HFP-1&lt;br /&gt;Rockville, MD 20857&lt;/li&gt;&lt;li&gt;Phone 301-827-2895&lt;/li&gt;&lt;li&gt;FAX: 301-827-4050&lt;br /&gt;e-mail:&amp;nbsp; RCAC@fda.hhs.gov&lt;/li&gt;&lt;li&gt;&lt;strong&gt;FDA Advisory Committee Information Line&lt;/strong&gt;&lt;br /&gt;1-800-741-8138&lt;br /&gt;301-443-0572 in the Washington, DC, area&lt;br /&gt;code 8732112560&lt;br /&gt;Please call the Information Line for up-to-date information on this meeting.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting.&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Lee L. Zwanziger at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at &amp;nbsp;&lt;a href="/oc/advisory/default.htm"&gt;http://www.fda.gov/AdvisoryCommittees/&lt;/a&gt; for procedures on public conduct during advisory committee meetings.&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).&lt;/p&gt;&lt;p align="center"&gt;&amp;nbsp;&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
